Ezitimibe in association with simvastatin shows increase in cancer risk in
five year study.
The combination is marketed as Vytorin and Inegy.
A recent exhaustive study found no carcinogenic proprties in statins so
Ezitimibe appears to be the culprit.
http://www.fda.gov/medwatch/safety/2008/safety08.htm#ezetimibe2
